{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T14:51:52Z","timestamp":1785595912434,"version":"3.56.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,1]],"date-time":"2023-08-01T00:00:00Z","timestamp":1690848000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2023,8]]},"DOI":"10.1007\/s00520-023-07973-3","type":"journal-article","created":{"date-parts":[[2023,8,2]],"date-time":"2023-08-02T03:22:36Z","timestamp":1690946556000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":7,"title":["Risk factor analysis for anti-epidermal growth factor receptor monoclonal antibody\u2013induced skin toxicities in real-world metastatic colorectal cancer treatment"],"prefix":"10.1007","volume":"31","author":[{"given":"Yoshitaka","family":"Saito","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kazuki","family":"Uchiyama","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoh","family":"Takekuma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yoshito","family":"Komatsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mitsuru","family":"Sugawara","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,8,2]]},"reference":[{"key":"7973_CR1","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1016\/j.clcc.2020.01.001","volume":"19","author":"G Kafatos","year":"2020","unstructured":"Kafatos G, Dube S, Burdon P, Demonty G, Flinois A, Leclerc M et al (2020) Management of EGFR inhibitor-induced skin toxicity and factors impacting patients\u2019 adherence to skin toxicity treatment: health care provider and patient surveys in European Oncology Centers. Clin Colorectal Cancer 19:100\u2013108","journal-title":"Clin Colorectal Cancer"},{"issue":"2005","key":"7973_CR2","first-page":"0010","volume":"1","author":"K Oda","year":"2005","unstructured":"Oda K, Matsuoka Y, Funahashi A, Kitano H (2005) A comprehensive pathway map of epidermal growth factor receptor signaling. Mol Syst Biol 1(2005):0010","journal-title":"Mol Syst Biol"},{"key":"7973_CR3","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1002\/path.2625","volume":"219","author":"J Abubaker","year":"2009","unstructured":"Abubaker J, Bavi P, Al-Haqawi W, Sultana M, Al-Harbi S, Al-Sanea N et al (2009) Prognostic significance of alterations in KRAS isoforms KRAS-4A\/4B and KRAS mutations in colorectal carcinoma. J Pathol 219:435\u2013445","journal-title":"J Pathol"},{"key":"7973_CR4","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1093\/jjco\/hyt062","volume":"43","author":"T Watanabe","year":"2013","unstructured":"Watanabe T, Yoshino T, Uetake H, Yamazaki K, Ishiguro M, Kurokawa T et al (2013) KRAS mutational status in Japanese patients with colorectal cancer: results from a nationwide, multicenter, cross-sectional study. Jpn J Clin Oncol 43:706\u2013712","journal-title":"Jpn J Clin Oncol"},{"key":"7973_CR5","doi-asserted-by":"publisher","first-page":"179","DOI":"10.1200\/JCO.2015.63.9674","volume":"34","author":"CJ Allegra","year":"2016","unstructured":"Allegra CJ, Rumble RB, Hamilton SR, Mangu PB, Roach N, Hantel A et al (2016) Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology provisional clinical opinion update 2015. J Clin Oncol 34:179\u2013185","journal-title":"J Clin Oncol"},{"key":"7973_CR6","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1056\/NEJMoa033025","volume":"351","author":"D Cunningham","year":"2004","unstructured":"Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A et al (2004) Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337\u2013345","journal-title":"N Engl J Med"},{"key":"7973_CR7","doi-asserted-by":"publisher","first-page":"1626","DOI":"10.1200\/JCO.2007.14.7116","volume":"26","author":"RG Amado","year":"2008","unstructured":"Amado RG, Wolf M, Peeters M, Van Cutsem E, Siena S, Freeman DJ et al (2008) Wild-type KRAS is required for panitumumab efficacy in patients with metastatic colorectal cancer. J Clin Oncol 26:1626\u20131634","journal-title":"J Clin Oncol"},{"key":"7973_CR8","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa0805019","volume":"360","author":"E Van Cutsem","year":"2009","unstructured":"Van Cutsem E, K\u00f6hne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A et al (2009) Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. N Engl J Med 360:1408\u20131417","journal-title":"N Engl J Med"},{"key":"7973_CR9","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/S1470-2045(14)70330-4","volume":"15","author":"V Heinemann","year":"2014","unstructured":"Heinemann V, von Weikersthal LF, Decker T, Kiani A, Vehling-Kaiser U, Al-Batran SE et al (2014) FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (FIRE-3): a randomised, open-label, phase 3 trial. Lancet Oncol 15:1065\u20131075","journal-title":"Lancet Oncol"},{"key":"7973_CR10","doi-asserted-by":"publisher","first-page":"4697","DOI":"10.1200\/JCO.2009.27.4860","volume":"28","author":"JY Douillard","year":"2010","unstructured":"Douillard JY, Siena S, Cassidy J, Tabernero J, Burkes R, Barugel M et al (2010) Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study. J Clin Oncol 28:4697\u20134705","journal-title":"J Clin Oncol"},{"key":"7973_CR11","doi-asserted-by":"publisher","first-page":"4706","DOI":"10.1200\/JCO.2009.27.6055","volume":"28","author":"M Peeters","year":"2010","unstructured":"Peeters M, Price TJ, Cervantes A, Sobrero AF, Ducreux M, Hotko Y et al (2010) Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer. J Clin Oncol 28:4706\u20134713","journal-title":"J Clin Oncol"},{"key":"7973_CR12","doi-asserted-by":"publisher","first-page":"2311","DOI":"10.1200\/JCO.2007.13.1193","volume":"26","author":"AF Sobrero","year":"2008","unstructured":"Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W, Abubakr YA, Lutz MP et al (2008) EPIC: phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in patients with metastatic colorectal cancer. J Clin Oncol 26:2311\u20132319","journal-title":"J Clin Oncol"},{"key":"7973_CR13","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1159\/000486338","volume":"94","author":"F Petrelli","year":"2018","unstructured":"Petrelli F, Ardito R, Ghidini A, Zaniboni A, Ghidini M, Barni S (2018) Different toxicity of cetuximab and panitumumab in metastatic colorectal cancer treatment: a systematic review and meta-analysis. Oncology 94:191\u2013199","journal-title":"Oncology"},{"key":"7973_CR14","doi-asserted-by":"publisher","first-page":"120","DOI":"10.1159\/000229751","volume":"77","author":"A Jatoi","year":"2009","unstructured":"Jatoi A, Green EM, Rowland KM, Sargent DJ, Alberts SR (2009) Clinical predictors of severe cetuximab-induced rash: observations from 933 patients enrolled in north central cancer treatment group study N0147. Oncology 77:120\u2013123","journal-title":"Oncology"},{"key":"7973_CR15","doi-asserted-by":"publisher","first-page":"100246","DOI":"10.1016\/j.esmoop.2021.100246","volume":"6","author":"A Raimondi","year":"2021","unstructured":"Raimondi A, Fuc\u00e0 G, Leone AG, Lonardi S, Antoniotti C, Smiroldo V et al (2021) Impact of age and gender on the efficacy and safety of upfront therapy with panitumumab plus FOLFOX followed by panitumumab-based maintenance: a pre-specified subgroup analysis of the Valentino study. ESMO Open 6:100246","journal-title":"ESMO Open"},{"key":"7973_CR16","doi-asserted-by":"publisher","first-page":"1427","DOI":"10.1200\/JCO.2007.12.4602","volume":"26","author":"F Graziano","year":"2008","unstructured":"Graziano F, Ruzzo A, Loupakis F, Canestrari E, Santini D, Catalano V et al (2008) Pharmacogenetic profiling for cetuximab plus irinotecan therapy in patients with refractory advanced colorectal cancer. J Clin Oncol 26:1427\u20131434","journal-title":"J Clin Oncol"},{"key":"7973_CR17","doi-asserted-by":"publisher","first-page":"3536","DOI":"10.1200\/JCO.2005.09.100","volume":"23","author":"D Vallb\u00f6hmer","year":"2005","unstructured":"Vallb\u00f6hmer D, Zhang W, Gordon M, Yang DY, Yun J, Press OA et al (2005) Molecular determinants of cetuximab efficacy. J Clin Oncol 23:3536\u20133544","journal-title":"J Clin Oncol"},{"key":"7973_CR18","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/cas.12642","volume":"106","author":"N Takahashi","year":"2015","unstructured":"Takahashi N, Yamada Y, Furuta K, Nagashima K, Kubo A, Sasaki Y et al (2015) Association between serum ligands and the skin toxicity of anti-epidermal growth factor receptor antibody in metastatic colorectal cancer. Cancer Sci 106:604\u2013610","journal-title":"Cancer Sci"},{"key":"7973_CR19","doi-asserted-by":"publisher","first-page":"2716","DOI":"10.1038\/bjc.2014.230","volume":"110","author":"N Takahashi","year":"2014","unstructured":"Takahashi N, Yamada Y, Furuta K, Honma Y, Iwasa S, Takashima A et al (2014) Serum levels of hepatocyte growth factor and epiregulin are associated with the prognosis on anti-EGFR antibody treatment in KRAS wild-type metastatic colorectal cancer. Br J Cancer 110:2716\u20132727","journal-title":"Br J Cancer"},{"key":"7973_CR20","doi-asserted-by":"publisher","first-page":"887","DOI":"10.3748\/wjg.v22.i2.887","volume":"22","author":"A Kubo","year":"2016","unstructured":"Kubo A, Hashimoto H, Takahashi N, Yamada Y (2016) Biomarkers of skin toxicity induced by anti-epidermal growth factor receptor antibody treatment in colorectal cancer. World J Gastroenterol 22:887\u2013894","journal-title":"World J Gastroenterol"},{"key":"7973_CR21","doi-asserted-by":"publisher","first-page":"1351","DOI":"10.1200\/JCO.2008.21.7828","volume":"28","author":"ME Lacouture","year":"2010","unstructured":"Lacouture ME, Mitchell EP, Piperdi B, Pillai MV, Shearer H, Iannotti N et al (2010) Skin toxicity evaluation protocol with panitumumab (STEPP), a phase II, open-label, randomized trial evaluating the impact of a pre-emptive skin treatment regimen on skin toxicities and quality of life in patients with metastatic colorectal cancer. J Clin Oncol 28:1351\u20131357","journal-title":"J Clin Oncol"},{"key":"7973_CR22","doi-asserted-by":"publisher","first-page":"617","DOI":"10.2217\/fon.14.251","volume":"11","author":"Y Kobayashi","year":"2015","unstructured":"Kobayashi Y, Komatsu Y, Yuki S, Fukushima H, Sasaki T, Iwanaga I et al (2015) Randomized controlled trial on the skin toxicity of panitumumab in Japanese patients with metastatic colorectal cancer: HGCSG1001 study; J-STEPP. Future Oncol 11:617\u2013627","journal-title":"Future Oncol"},{"key":"7973_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10147-020-01818-3","volume":"26","author":"K Aogi","year":"2021","unstructured":"Aogi K, Takeuchi H, Saeki T, Aiba K, Tamura K, Iino K et al (2021) Optimizing antiemetic treatment for chemotherapy-induced nausea and vomiting in Japan: update summary of the 2015 Japan Society of Clinical Oncology Clinical Practice Guidelines for Antiemesis. Int J Clin Oncol 26:1\u201317","journal-title":"Int J Clin Oncol"},{"key":"7973_CR24","doi-asserted-by":"publisher","first-page":"1079","DOI":"10.1007\/s00520-011-1197-6","volume":"19","author":"ME Lacouture","year":"2011","unstructured":"Lacouture ME, Anadkat MJ, Bensadoun RJ, Bryce J, Chan A, Epstein JB et al (2011) Clinical practice guidelines for the prevention and treatment of EGFR inhibitor-associated dermatologic toxicities. Support Care Cancer 19:1079\u20131095","journal-title":"Support Care Cancer"},{"key":"7973_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1007\/s40261-019-00811-7","volume":"39","author":"MC Annunziata","year":"2019","unstructured":"Annunziata MC, De Stefano A, Fabbrocini G, Leo S, Marchetti P, Romano MC et al (2019) Current recommendations and novel strategies for the management of skin toxicities related to anti-EGFR therapies in patients with metastatic colorectal cancer. Clin Drug Investig 39:825\u2013834","journal-title":"Clin Drug Investig"},{"key":"7973_CR26","doi-asserted-by":"publisher","first-page":"1483","DOI":"10.1634\/theoncologist.2016-0051","volume":"21","author":"RD Hofheinz","year":"2016","unstructured":"Hofheinz RD, Deplanque G, Komatsu Y, Kobayashi Y, Ocvirk J, Racca P et al (2016) Recommendations for the prophylactic management of skin reactions induced by epidermal growth factor receptor inhibitors in patients with solid tumors. Oncologist 21:1483\u20131491","journal-title":"Oncologist"},{"key":"7973_CR27","doi-asserted-by":"publisher","first-page":"810","DOI":"10.1200\/JCO.2015.62.3918","volume":"34","author":"B Melosky","year":"2016","unstructured":"Melosky B, Anderson H, Burkes RL, Chu Q, Hao D, Ho V et al (2016) Pan Canadian rash trial: a randomized phase iii trial evaluating the impact of a prophylactic skin treatment regimen on epidermal growth factor receptor-tyrosine kinase inhibitor-induced skin toxicities in patients with metastatic lung cancer. J Clin Oncol 34:810\u2013815","journal-title":"J Clin Oncol"},{"key":"7973_CR28","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.lungcan.2015.03.019","volume":"88","author":"O Arrieta","year":"2015","unstructured":"Arrieta O, Vega-Gonz\u00e1lez MT, L\u00f3pez-Mac\u00edas D, Mart\u00ednez-Hern\u00e1ndez JN, Bacon-Fonseca L, Macedo-P\u00e9rez EO et al (2015) Randomized, open-label trial evaluating the preventive effect of tetracycline on afatinib induced-skin toxicities in non-small cell lung cancer patients. Lung Cancer 88:282\u2013288","journal-title":"Lung Cancer"},{"key":"7973_CR29","first-page":"6175","volume":"35","author":"M Yamada","year":"2015","unstructured":"Yamada M, Iihara H, Fujii H, Ishihara M, Matsuhashi N, Takahashi T et al (2015) Prophylactic effect of oral minocycline in combination with topical steroid and skin care against panitumumab-induced acneiform rash in metastatic colorectal cancer patients. Anticancer Res 35:6175\u20136181","journal-title":"Anticancer Res"},{"key":"7973_CR30","doi-asserted-by":"publisher","first-page":"2621","DOI":"10.1007\/s00384-021-04002-9","volume":"36","author":"K Nakata","year":"2021","unstructured":"Nakata K, Komori T, Saso K, Ota H, Kagawa Y, Morita S et al (2021) Pre-emptive oral clarithromycin reduces the skin toxicity of panitumumab treatment for metastatic colorectal cancer. Int J Colorectal Dis 36:2621\u20132627","journal-title":"Int J Colorectal Dis"},{"issue":"4","key":"7973_CR31","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1016\/j.mcna.2011.03.012","volume":"95","author":"JM Zuckerman","year":"2011","unstructured":"Zuckerman JM, Qamar F, Bono BR (2011) Review of macrolides (azithromycin, clarithromycin), ketolids (telithromycin) and glycylcyclines (tigecycline). Med Clin North Am 95(4):761\u2013791","journal-title":"Med Clin North Am"},{"key":"7973_CR32","doi-asserted-by":"publisher","first-page":"524","DOI":"10.1093\/annonc\/mdq387","volume":"22","author":"K Potthoff","year":"2011","unstructured":"Potthoff K, Hofheinz R, Hassel JC, Volkenandt M, Lordick F, Hartmann JT et al (2011) Interdisciplinary management of EGFR-inhibitor-induced skin reactions: a German expert opinion. Ann Oncol 22:524\u2013535","journal-title":"Ann Oncol"},{"key":"7973_CR33","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/BF02361238","volume":"29","author":"T Ueda","year":"1994","unstructured":"Ueda T, Shimada E, Urakawa T (1994) Serum levels of cytokines in patients with colorectal cancer: possible involvement of interleukin-6 and interleukin-8 in hematogenous metastasis. J Gastroenterol 29:423\u2013429","journal-title":"J Gastroenterol"},{"key":"7973_CR34","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1007\/s00384-020-03748-y","volume":"36","author":"M Suenaga","year":"2021","unstructured":"Suenaga M, Mashima T, Kawata N, Wakatsuki T, Dan S, Seimiya H et al (2021) Serum IL-8 level as a candidate prognostic marker of response to anti-angiogenic therapy for metastatic colorectal cancer. Int J Colorectal Dis 36:131\u2013139","journal-title":"Int J Colorectal Dis"},{"key":"7973_CR35","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1186\/1471-2407-14-542","volume":"14","author":"TD Hamilton","year":"2014","unstructured":"Hamilton TD, Leugner D, Kopciuk K, Dixon E, Sutherland FR, Bathe OF (2014) Identification of prognostic inflammatory factors in colorectal liver metastases. BMC Cancer 14:542","journal-title":"BMC Cancer"},{"key":"7973_CR36","first-page":"31","volume":"68","author":"CG Larsen","year":"1989","unstructured":"Larsen CG, Anderson AO, Oppenheim JJ, Matsushima K (1989) Production of interleukin-8 by human dermal fibroblasts and keratinocytes in response to interleukin-1 or tumour necrosis factor. Immunology 68:31\u201336","journal-title":"Immunology"},{"key":"7973_CR37","doi-asserted-by":"publisher","first-page":"2589","DOI":"10.1002\/ijc.24269","volume":"124","author":"TK Hoffmann","year":"2009","unstructured":"Hoffmann TK, Schirlau K, Sonkoly E, Brandau S, Lang S, Pivarcsi A et al (2009) A novel mechanism for anti-EGFR antibody action involves chemokine-mediated leukocyte infiltration. Int J Cancer 124:2589\u20132596","journal-title":"Int J Cancer"},{"key":"7973_CR38","doi-asserted-by":"publisher","first-page":"e39706","DOI":"10.1371\/journal.pone.0039706","volume":"7","author":"N Bangsgaard","year":"2012","unstructured":"Bangsgaard N, Houtkamp M, Schuurhuis DH, Parren PW, Baadsgaard O, Niessen HW et al (2012) Neutralization of IL-8 prevents the induction of dermatologic adverse events associated with the inhibition of epidermal growth factor receptor. PLoS One 7:e39706","journal-title":"PLoS One"},{"key":"7973_CR39","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1006\/excr.1996.0274","volume":"227","author":"WR Reenstra","year":"1996","unstructured":"Reenstra WR, Yaar M, Gilchrest BA (1996) Aging affects epidermal growth factor receptor phosphorylation and traffic kinetics. Exp Cell Res 227:252\u2013255","journal-title":"Exp Cell Res"},{"key":"7973_CR40","doi-asserted-by":"publisher","first-page":"194","DOI":"10.1196\/annals.1386.006","volume":"1089","author":"A Migliaccio","year":"2006","unstructured":"Migliaccio A, Castoria G, Di Domenico M, Ciociola A, Lombardi M, De Falco A et al (2006) Crosstalk between EGFR and extranuclear steroid receptors. Ann N Y Acad Sci 1089:194\u2013200","journal-title":"Ann N Y Acad Sci"},{"key":"7973_CR41","doi-asserted-by":"publisher","first-page":"491","DOI":"10.1186\/s12885-022-09599-w","volume":"22","author":"R Du","year":"2022","unstructured":"Du R, Yang H, Zhou H, Ma L, Getu MA, Chen C et al (2022) The relationship between medication literacy and skin adverse reactions in non-small-cell lung cancer patients undergoing targeted EGFR-TKI therapy. BMC Cancer 22:491","journal-title":"BMC Cancer"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07973-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00520-023-07973-3\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-023-07973-3.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,11]],"date-time":"2023-08-11T08:19:44Z","timestamp":1691741984000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00520-023-07973-3"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,8]]}},"alternative-id":["7973"],"URL":"https:\/\/doi.org\/10.1007\/s00520-023-07973-3","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8]]},"assertion":[{"value":"5 April 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"25 July 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in this study involving human participants were performed in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. For this type of study, the need for formal consent was waived by the Ethical Review Board for Life Science and Medical Research at Hokkaido University Hospital.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Formal consent was not required for this type of study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"YS, KU, YT, and MS have no conflicts of interest. YK reports receiving grants and personal fees from Ono, TAIHO, CHUGAI, Eli Lilly, Yakult, Bristol-Myers, Merck, Takeda, Novartis, Bayer, and Daiichi-Sankyo and grants from Iqvia outside the submitted work.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}],"article-number":"504"}}